NASDAQ:SYRS

Syros Pharmaceuticals Stock Forecast

etoro logo Buy SYRS
*Your capital is at risk
$0.0001
+0 (+0%)
At Close: Jul 02, 2026
AI Analysis AI Analysis of SYRS AI-Powered Market Insights
Stock Analysis PRO New!
Risk Assessment PRO New!
Trading Strategy PRO New!
Add SYRS to Watchlist?
  • Easy Tracking In The Watchlist
PDF

Red day on Thursday for Syros Pharmaceuticals
(Updated on Jul 02, 2026)

Sell candidate since Jun 23, 2026

No changes to the price of Syros Pharmaceuticals stock on the last trading day (Thursday, 2nd Jul 2026). During the last trading day the stock fluctuated 0% from a day low at $0.0001 to a day high of $0.0001. The price has been going up and down for this period, and there has been a -75% loss for the last 2 weeks.

The stock lies in the lower of a very wide and falling trend in the short term, and this may normally pose a very good buying opportunity. If the lower trend floor at $0.00008251114301 is broken, it will firstly indicate a stronger fall rate. Given the current short-term trend, the stock is expected to fall -15.44% during the next 3 months and, with a 90% probability hold a price between $0.00006977135396 and $0.0003 at the end of this 3-month period.

SYRS Signals & Forecast

Volume gained on the last day while the price remained unchanged. This is not a classical divergence, but the stock should be watched more closely at it may be a "turning point". The very low volume increases the risk and reduces the other technical signals issued. Some negative signals were issued as well, and these may have some influence on the near short-term development. The Syros Pharmaceuticals stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $0.0001 and $0.0002. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Thursday, June 18, 2026, and so far it has fallen -75.00%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD).

Support, Risk & Stop-loss for Syros Pharmaceuticals stock

There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days.

This stock may move very much during the day (volatility) and with a very large prediction interval from the Bollinger Band this stock is considered to be "very high risk". During the last day, the stock moved $0 between high and low, or 0%. For the last week, the stock has had daily average volatility of 60.00%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (SYRS) For The Upcoming Trading Day Of Monday 6th

For the upcoming trading day on Monday, 6th we expect Syros Pharmaceuticals to open at $0.0001, and during the day (based on 14 day Average True Range), to move between $0.0000354355835 and $0.0002, which gives a possible trading interval of +/-$0.0001 (+/-364.40%) up or down from last closing price. If Syros Pharmaceuticals takes out the full calculated possible swing range there will be an estimated 364.40% move between the lowest and the highest trading price during the day.

Is Syros Pharmaceuticals stock A Buy?

Syros Pharmaceuticals holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

Current score: -6.236 Strong Sell Candidate Unchanged

Predicted Fair Opening Price

Predicted fair opening price on July 6, 2026 - $0.0001 ( 0%).

Want to trade but not sure how? Our step-by-step guide can help.
Skip the guide? Open account with our trusted broker* eToro
*Your capital is at risk

SYRS Performance

Trading levels for SYRS

StockInvest.us
Full Access. No Commitment. 7 Days Free!
Long & Short-Term Golden Star Lists
AI Stock Analysis*
Top 10 Candidates on Every List
Premium Lists
Ad-FREE Browsing
Advanced Stock Screener

Fibonacci Support & Resistance Levels

Level Price
R3 0.0001 -
R2 0.0001 -
R1 0.0001 -
Price 0.0001
S1 0.0001 -
S2 0.0001 -
S3 0.0001 -

Accumulated Volume Support & Resistance Levels

Level Price
R3 0 -
R2 0 -
R1 0 -
Price 0.0001
S1 0 -
S2 0 -
S3 0 -

FAQ

What is the symbol for Syros Pharmaceuticals Stock and on which exchange is it traded?
The symbol for Syros Pharmaceuticals is SYRS and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Syros Pharmaceuticals Stock?
Syros Pharmaceuticals holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

How to buy Syros Pharmaceuticals Stock?
Syros Pharmaceuticals Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Syros Pharmaceuticals Stock.

What's the current price of Syros Pharmaceuticals Stock?
As of the end of day on the Jul 02, 2026, the price of an Syros Pharmaceuticals (SYRS) share was $0.0001.

What is the 52-week high and low for Syros Pharmaceuticals Stock?
The 52-week high for Syros Pharmaceuticals Stock is $0.0400 and the 52-week low is $0.000001.

What is the market capitalization of Syros Pharmaceuticals Stock?
As of the Jul 02, 2026, the market capitalization of Syros Pharmaceuticals is 2.683K.

When is the next earnings date for Syros Pharmaceuticals?
The upcoming earnings date for Syros Pharmaceuticals is Jul 29, 2026.
Click to get the best stock tips daily for free!
ABOUT SYROS PHARMACEUTICALS
Syros Pharmaceuticals
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acu...
GOLDEN STAR
Ticker Change Signal Date
B
BXDC
$21.71
1.11% Jun 29
SRPT
$17.02
13.28% Jun 29
OSIS
$218.29
1.59% Jun 26
NMRK
$15.02
4.66% Jun 24
JLL
$299.78
9.23% Jun 24

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE